Q3 2025 Lexicon Pharmaceuticals Inc Earnings Call Transcript

Nov 6, 2025 / 01:30 PM GMT

Release Date Price: $1.43 (+3.62%)

Transcript 10-Q8-K

Key Points

Positve

Lexicon Pharmaceuticals Inc (LXRX) reported a significant increase in total revenue for Q3 2025, reaching $14.2 million compared to $1.8 million in Q3 2024.
The company has made substantial progress in its R&D pipeline, particularly with pilivapidin, which is ready for phase 3 trials in diabetic peripheral neuropathic pain.
Lexicon Pharmaceuticals Inc (LXRX) has successfully reduced operating expenses, reflecting a strategic repositioning towards R&D focus.
The company has established strong partnerships, including an exclusive agreement with Novo Nordisk for LX 9,851, which could lead to milestone payments.
Lexicon Pharmaceuticals Inc (LXRX) is actively engaging with the FDA and has made progress in discussions regarding Zinquista for type 1 diabetes.

Negative

Despite revenue growth, Lexicon Pharmaceuticals Inc (LXRX) reported a net loss of $12.8 million for Q3 2025.
The company experienced a decrease in cash reserves, ending the quarter with $145 million compared to $238 million at the end of 2024.
There are ongoing uncertainties regarding the FDA's feedback and approval process for Zinquista in type 1 diabetes.
The company is still in the process of identifying a partner for pilivapidin, with discussions contingent on the outcome of the end of phase 2 meeting with the FDA.
Lexicon Pharmaceuticals Inc (LXRX) faces challenges in the competitive landscape, particularly in the hypertrophic cardiomyopathy space with emerging treatments like CMIs.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LXRX.OQ - Lexicon Pharmaceuticals Inc
Q3 2025 Lexicon Pharmaceuticals Inc Earnings Call
Nov 06, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Lexicon Pharmaceuticals 3rd quarter 2025 financial results conference call. At this time, all participants are in listen in mode.

Following the management's prepared remarks, we will hold a brief question-and-answer session. As a reminder, this call is being recorded today, November 6, 2025. I will now turn the call over to Lisa DiFransco, senior Vice President for investor relations and corporate communications for Lexicon. Please go ahead, Lisa.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Mila. Good morning and welcome to our

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.